EKF Diagnostics Holdings PLC PDMR/ PCA Dealings (0981O)
05 Octubre 2021 - 09:00AM
UK Regulatory
TIDMEKF
RNS Number : 0981O
EKF Diagnostics Holdings PLC
05 October 2021
EKF Diagnostics Holdings plc
("EKF" or the "Company")
PDMR/ PCA Dealings
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business, announces that the Board of EKF has been
informed that on Friday 1 October, 2021, certain funds connected to
Christopher Mills, Non-executive Chairman, sold a total of
1,275,000 ordinary shares of 1 pence each in the Company ("Ordinary
Shares") at a price of 84.0 pence per Ordinary Share.
Following this transaction, Christopher Mills' total direct and
indirect interest in the Company is 130,875,000 Ordinary Shares,
representing approximately 28.76% of the total voting rights over
the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK
MAR is set out below and reflects the sale of 637,500 Ordinary
Shares by each of the North Atlantic Smaller Companies Investment
Trust plc ("NASCIT") and the Oryx International Growth Fund Limited
("Oryx").
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Christopher Mills
--------------------------------------- --------------------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------------------
a) Position/status Christopher Mills is Non-executive
Chairman of the Company.
Mr. Mills is a partner and Chief
Investment Officer of Harwood Capital
LLP. Harwood Capital LLP is Investment
Manager to NASCIT.
Mr Mills is also a director of Harwood
Capital Management (Gibraltar) Limited,
which is Investment Manager and Investment
Adviser to Oryx.
--------------------------------------- --------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------------------- --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------------------
a) Name EKF Diagnostics Holdings plc
--------------------------------------- --------------------------------------------------
b) LEI 213800DXTF3EAUK1AR05
--------------------------------------- --------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 each
financial instrument,
type of instrument
Identification code GB0031509804
b) Nature of the transaction Sale of shares
--------------------------------------- --------------------------------------------------
c) Price(s) and volume(s)
----------------------- ----------------------
Price(s) Volume(s)
----------------------- ----------------------
GBP0.84 637,500
-------------------------------------------------------------------- ----------------------
GBP0.84 637,500
-------------------------------------------------------------------- ----------------------
d) Aggregated information
- Aggregated volume 1,275,000
- Price GBP0.84
e) Date of the transaction 1 October 2021
--------------------------------------- --------------------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------------- --------------------------------------------------
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0)29 2071 0570
Mike Salter, CEO
Richard Evans, FD & COO
Singer Capital Markets (Nominated Adviser & Joint Tel: +44 ( 0)20 7496 3000
Broker)
Aubrey Powell / George Tzimas / Tom
Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUPGCCUUPGGWA
(END) Dow Jones Newswires
October 05, 2021 10:00 ET (14:00 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024